1. AGN works by inhibiting calcium release from the synapses of the Glun2B receptor on glutamate and hence the calcium cannot travel across the synapses via TRPC channels
2. NYR works by avoiding glutamate completely and blocks the calcium TRPC channels from allowing calcium to travel across
Essentially they work on the same thing calcium influx. AGN however is in a class of drug that’s failed because blocking the GLun2b receptor also blocks the Glun2a receptor which is needed to allow neurons to survive it’s why other drugs in the same class as AGN have failed. NYR is first of its kind and avoids this problem completely.
Important for us investors AGN proves any sort of efficacy in the next 3-4 months, this proves up NYR as well for its mechanism of action of calcium. I sold AGN because of this risk of unnecessarily inhibiting the receptor Glun2a and the class of drug it’s in has failed multiple times before in the past. Also for avoiding glutamate completely NYR can be dosed over multiple days for secondary brain injury and protect the heart muscle.
NYR is too big for AGN and the 20 million market for NYR is a joke and will change
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)